Lupus anticoagulants (LA) are heterogeneous autoantibodies of the IgG and IgM type directly directed against a variety of anionic phospholipids such as cardiolipin, phosphatidylserine or phosphatidylinositol or against proteins having the capacity to bind to phospholipids such as β2-glycoprotein I (β2-GPI).
The presence of LA is primarily detected using sensitive in vitro tests using phospholipids, such as TCA (Activated Partial Time) or dRVVT. They have the in vitro capacity to prolong phospholipid-dependent clotting times but are most often associated with thrombotic complications in vivo (venous or arterial thrombosis, thrombocytopenia and fetal losses) and do not predispose to a risk of bleeding. DRVVT is routinely used in screening for LA. It is considered specific and robust.
Each batch is supplied with a certificate of analysis showing the following results :
- TCA (sensitive lupus)
- TCA (1: 1 Pool mix)
- TCA on silica (SCT)
- Kaolin Clotting Time
- DRVVT report
- LA hexagonal phase
- PNP (platelet neutralization) IgG / IgA / IgM for :
Anti-cardiolipin
Anti-β-2-glycoprotein 1
Anti-phosphatidylserine
Expiration date of 3 years from the date of manufacture with storage between -40 °C and -80 °C
Easily adaptable, the reagent is designed for use on most hemostasis analyzers.
- 25 cryotubes x 0.5 mL or 1 mL of frozen plasma
